Life sciences investment platform launched
Experienced life sciences investment manager Deepbridge Capital has announced the launch of Deepbridge Syndicate, an online investment platform created to facilitate investment by elective professional investors in to healthcare innovation.
Deepbridge has invested in over 35 life sciences companies to date and aims to provide Deepbridge Syndicate investors with the reassurance of their ongoing engagement and investment in rigorously selected investment opportunities.
Investing in life sciences has never been more vital, with the ageing population, prevalence of mental health concerns and the ever-increasing pressure on national and international healthcare services. There is a growing need and market for medical innovation, and these are being developed at a faster rate than ever before, providing considerable opportunities for investors to access growth-focused and revenue generating investment opportunities.
The UK life sciences sector is unique and can represent a challenging environment for even experienced investors to identify appropriate opportunities and value. Deepbridge’s sector experience enables investors to better identify life sciences growth opportunities, which have been appropriately valued and will be actively managed by the Deepbridge life sciences team, headed by Dr Savvas Neophytou.
Investors via Deepbridge Syndicate must qualify to be treated as an Elective Professional Client in line with the definition of the Market in Financial Instruments Directive.
Deepbridge Syndicate: www.deepbridgesyndicate.com
Ian Warwick, Managing Partner at Deepbridge Capital, commented;
“The UK is at the global forefront of life sciences innovation, on a par with premier life science destinations such as Boston, San Francisco, San Diego and Singapore. The UK sector consists of over 5,700 companies employing over 231,000 with an annual turnover of around £61.8bn. The rising wealth in emerging economies such as China, India and Brazil continues to open up new opportunities for medical and biopharmaceutical companies.
“Deepbridge Syndicate aims to open up this market potential to the individual investor. Traditionally, investing in Life Sciences hasn’t been easy to access for many investors as the technologies, valuations and exits opportunities are often difficult calculate, but with the due diligence and proactive management from Deepbridge Capital and online access to key documents and updates via the Syndicate, investors are constantly in touch with the progress of their investment. A majority of the portfolio companies also benefit from the UK Government’s Enterprise Investment Scheme (EIS), which provides considerable tax relief to those investing in these higher risk companies.”
Deepbridge Syndicate is launching with 3 Life Sciences companies on the platform, all of which have also received funding via the Deepbridge Technology Growth EIS or Deepbridge Life Sciences (S)EIS portfolios:
You can Register here for regular updates on our investment opportunities:
 Source: the Strength & Opportunities report issued in 2015
For further information please contact:
Syndicate Manager, Deepbridge Capital
About Deepbridge Syndicate
Deepbridge Syndicate is an online capital raising platform that provides an opportunity for Private investors (with Elective Professional Client status) to invest directly into innovative Life Science companies. Joining experienced VC investment in funding the advancement of Healthcare, whilst benefiting from the considerable tax reliefs provided through the Enterprise Investment Scheme.
By working alongside the highly experienced Life Science team at Deepbridge Capital, all investee companies have been subjected to a thorough degree of due diligence and valuation by a team with over 200 years’ worth of combined cross-sector commercial experience, and will have ongoing engagement, mentoring and support from the team for the lifetime of the investment.
Investing via Deepbridge Syndicate is fee-free for investors and subject to a minimum investment of £10,000.
About Deepbridge Capital LLP
Deepbridge Syndicate is a marketing style of Deepbridge Capital LLP, which is authorised and regulated by the FCA and is operated by a highly experienced, hands-on team who work closely with investee companies to deliver targeted growth outcomes. Deepbridge is a different kind of investment manager and adviser. Deepbridge works closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. Deepbridge also partners with innovative and committed management teams to help UK based companies realise their potential and become successful leading-edge businesses.
Deepbridge operates across four principle divisions:
- disruptive technology
- life sciences
- renewable energy
- sustainable technologies.
This document is not a solicitation to any person to invest in the Deepbridge Funds and should be regarded merely as an advertisement. No such solicitation will be made except pursuant to the Deepbridge information memorandum for the Fund. Before making a decision to invest in the Deepbridge Funds, potential investors are advised to read the Information Memorandum carefully and to consult a suitable professional adviser. Further information on the potential merits and risks are available in the Risk Section of the Information Memorandum. Investments may go down as well as up and investors may not get back the full amount invested. Deepbridge does not provide legal, financial or taxation advice. Potential tax benefits depend on individual circumstances, may change in the future and are not guaranteed.
Deepbridge House, Honeycomb East, Chester Business Park, Chester CH4 9QN